BR112013024022A2 - agomelatina cristalina misturada (forma-viii), método de preparação e uso da mesma e composição farmacêutica contendo a mesma - Google Patents

agomelatina cristalina misturada (forma-viii), método de preparação e uso da mesma e composição farmacêutica contendo a mesma

Info

Publication number
BR112013024022A2
BR112013024022A2 BR112013024022A BR112013024022A BR112013024022A2 BR 112013024022 A2 BR112013024022 A2 BR 112013024022A2 BR 112013024022 A BR112013024022 A BR 112013024022A BR 112013024022 A BR112013024022 A BR 112013024022A BR 112013024022 A2 BR112013024022 A2 BR 112013024022A2
Authority
BR
Brazil
Prior art keywords
preparation
viii
pharmaceutical composition
forma
agomelatine
Prior art date
Application number
BR112013024022A
Other languages
English (en)
Inventor
Hanbin Shan
Qing Long
Xiong Yu
Xueyan Zhu
Yu Huang
Zhedong Yuan
Original Assignee
Servier Lab
Shanghai Inst Pharm Industry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Shanghai Inst Pharm Industry filed Critical Servier Lab
Publication of BR112013024022A2 publication Critical patent/BR112013024022A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/08—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

resumo patente de invenção: "agomelatina cristalina misturada (forma-viii), método de preparação e uso da mesma e composição farmacêutica contendo a mesma". a presente invenção refere-se a uma forma viii cristalina misturada da agomelatina, o seu método de preparação, aplicação e composição farmacêutica. o cristal misturado citado acima consiste principalmente na forma cristalina vi da agomelatina. a forma cristalina misturada citada acima é estável e tem a boa reprodutibilidade. através de testes de estabilidade, foi encontrado para ser superior à forma cristalina vi quanto a estabilidade. por conseguinte, a forma cristalina viii da presente invenção possui vantagens na preparação farmacêutica. 1/1
BR112013024022A 2011-03-23 2012-03-22 agomelatina cristalina misturada (forma-viii), método de preparação e uso da mesma e composição farmacêutica contendo a mesma BR112013024022A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2011100706340A CN102690209A (zh) 2011-03-23 2011-03-23 阿戈美拉汀的混晶(形式-ⅷ)、其制备方法、应用和包含其的药物组合物
PCT/CN2012/072818 WO2012126386A1 (zh) 2011-03-23 2012-03-22 阿戈美拉汀的混晶(形式-ⅷ)、其制备方法、应用和包含其的药物组合物

Publications (1)

Publication Number Publication Date
BR112013024022A2 true BR112013024022A2 (pt) 2016-12-06

Family

ID=46855965

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013024022A BR112013024022A2 (pt) 2011-03-23 2012-03-22 agomelatina cristalina misturada (forma-viii), método de preparação e uso da mesma e composição farmacêutica contendo a mesma

Country Status (30)

Country Link
US (1) US20140088197A1 (pt)
EP (1) EP2690088B1 (pt)
JP (1) JP6203171B2 (pt)
KR (1) KR20130136546A (pt)
CN (2) CN102690209A (pt)
AR (1) AR085915A1 (pt)
AU (1) AU2012231548B2 (pt)
BR (1) BR112013024022A2 (pt)
CA (1) CA2829690C (pt)
CY (1) CY1118751T1 (pt)
DK (1) DK2690088T3 (pt)
EA (1) EA023278B1 (pt)
ES (1) ES2626030T3 (pt)
GE (1) GEP201606567B (pt)
HK (1) HK1193086A1 (pt)
HR (1) HRP20170575T1 (pt)
HU (1) HUE034329T2 (pt)
LT (1) LT2690088T (pt)
MA (1) MA34959B1 (pt)
MD (1) MD4484C1 (pt)
ME (1) ME02731B (pt)
MX (1) MX355551B (pt)
MY (1) MY166444A (pt)
PL (1) PL2690088T3 (pt)
PT (1) PT2690088T (pt)
RS (1) RS55918B1 (pt)
SG (1) SG193305A1 (pt)
SI (1) SI2690088T1 (pt)
WO (1) WO2012126386A1 (pt)
ZA (1) ZA201306761B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12012000132A1 (en) * 2011-06-09 2014-10-20 Servier Lab New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them
MX369303B (es) * 2013-07-29 2019-11-05 Servier Lab Nuevos complejos de agomelatina y de acidos sulfonicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
CN104529804A (zh) * 2014-12-11 2015-04-22 连云港金康医药科技有限公司 阿戈美拉汀的新晶型
EP3075724B1 (en) 2015-03-31 2023-07-12 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Solid form of agomelatine
EP3466923A1 (en) 2017-10-09 2019-04-10 KRKA, d.d., Novo mesto Process for the preparation of agomelatine in crystalline form

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US7498466B2 (en) * 2004-02-13 2009-03-03 Les Laboratoires Servier Process for the synthesis and crystalline form of agomelatine
FR2866335B1 (fr) * 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine
FR2889521B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline iii de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2889523B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline v de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2889522B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline iv de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2923482B1 (fr) * 2007-11-09 2010-01-29 Servier Lab Nouvelle forme cristalline vi de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
CN101585779B (zh) * 2009-03-10 2014-04-02 上海医药工业研究院 阿戈美拉汀的晶型vi及其制备方法和应用
WO2011006387A1 (zh) * 2009-07-11 2011-01-20 浙江华海药业股份有限公司 阿戈美拉汀的制备方法、阿戈美拉汀晶形及其制备方法
CN101723844A (zh) * 2009-11-21 2010-06-09 浙江华海药业股份有限公司 一种阿戈美拉汀晶形b、它的制备方法和包含它的药物组合物
CN101955440B (zh) * 2009-07-17 2014-04-09 江苏万特制药有限公司 一种阿戈美拉汀新晶型及其制备方法
EP2319827A1 (en) * 2009-11-09 2011-05-11 Ratiopharm GmbH Process for the production of polymorph form I of agomelatine
CN101781226B (zh) * 2009-12-23 2012-03-28 天津泰普药品科技发展有限公司 阿戈美拉汀及其药物组合物
CN101792400B (zh) * 2010-03-16 2013-01-30 华东师范大学 一种阿戈美拉汀的合成方法
EP2580183B1 (en) * 2010-06-10 2014-07-23 Gador S.A. New process for the preparation of n-[2-(7-methoxy-1-naphthyl)-ethyl]acetamide
WO2012046253A2 (en) * 2010-10-08 2012-04-12 Msn Laboratories Limited Process for the preparation of n-[2- (7-methoxy-l-naphthyl) ethyl] acetamide and its novel crystalline forms
CN102452952A (zh) * 2010-11-03 2012-05-16 天津药物研究院 一种高纯度的i型阿戈美拉汀晶体制备方法

Also Published As

Publication number Publication date
MD4484C1 (ro) 2017-12-31
AU2012231548A1 (en) 2013-10-03
CA2829690C (en) 2016-08-09
CN103476743B (zh) 2015-02-25
MX355551B (es) 2018-04-23
EP2690088B1 (en) 2017-02-22
NZ615714A (en) 2016-03-31
EP2690088A4 (en) 2014-09-17
GEP201606567B (en) 2016-11-10
EA023278B1 (ru) 2016-05-31
KR20130136546A (ko) 2013-12-12
ME02731B (me) 2017-10-20
ZA201306761B (en) 2014-05-25
AR085915A1 (es) 2013-11-06
JP2014516921A (ja) 2014-07-17
LT2690088T (lt) 2017-04-10
JP6203171B2 (ja) 2017-09-27
MY166444A (en) 2018-06-27
MA34959B1 (fr) 2014-03-01
EA201301065A1 (ru) 2014-02-28
SG193305A1 (en) 2013-10-30
MD20130074A2 (en) 2014-03-31
RS55918B1 (sr) 2017-09-29
CY1118751T1 (el) 2017-07-12
HRP20170575T1 (hr) 2017-06-30
CA2829690A1 (en) 2012-09-27
CN102690209A (zh) 2012-09-26
HK1193086A1 (en) 2014-09-12
DK2690088T3 (en) 2017-06-06
MX2013010634A (es) 2013-10-07
EP2690088A1 (en) 2014-01-29
WO2012126386A1 (zh) 2012-09-27
MD4484B1 (ro) 2017-05-31
CN103476743A (zh) 2013-12-25
SI2690088T1 (sl) 2017-06-30
ES2626030T3 (es) 2017-07-21
HUE034329T2 (en) 2018-02-28
PL2690088T3 (pl) 2017-09-29
PT2690088T (pt) 2017-03-20
US20140088197A1 (en) 2014-03-27
AU2012231548B2 (en) 2015-11-19

Similar Documents

Publication Publication Date Title
BR112013024022A2 (pt) agomelatina cristalina misturada (forma-viii), método de preparação e uso da mesma e composição farmacêutica contendo a mesma
NI201500142A (es) Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos.
BR112013028816A2 (pt) "análogos de compstatina, composição que os compreende e uso dos mesmos".
BR112014003382A2 (pt) análogos de (e)-n'-(1-feniletilideno)benzo-hidrazida substituída como inibidores de histona desmetilase
BR112018012106A2 (pt) forma cristalina de inibidor de btk quinase e método de preparação da mesma
DOP2012000310A (es) Morfolinopirimidinas y su uso en terapia
DOP2014000133A (es) Triazolopiridinas sustituidas
BR112015024647A2 (pt) fórmula para bebês com um baixo teor de mcfas em proporções específicas e um teor relativamente alto de ácidos graxos insaturados, e seu uso na promoção do estabelecimento saudável da função cognitiva em bebês
BR112014029754B1 (pt) soluções de tensoativos que contêm n-metil-noleilglucaminas e n-metil-n-c12-c14 acilglucaminas e seu uso, processo para produzir composições cosméticas e composição
NI201500096A (es) Compuesto químicos
CU20120171A7 (es) Triazolopiridinas sustituidas
BR112015008170A2 (pt) cristal mono-hidratado de sal de potássio fimasartana, método para a preparação do mesmo e composição farmacológica compreendendo o mesmo
GT201300322A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
CL2007003042A1 (es) Compuestos derivados del acido tetrahidro-naftalen-1-carboxilico sustituidos con piperidina o piperazina; procedimiento de preparacion; compuesto intermediario; composicion farmaceutica; procedimiento de preparacion; y uso para el tratamiento de arte
BR112015011515A2 (pt) Composições farmacêuticas de inibidores de cetp
BR112014009760A2 (pt) análogos de ácido siálico, seu uso e composição farmacêutica e composição farmacêutica de liberação sustentada os compreendendo
BR112013024219A2 (pt) forma cristalina vii da agomelatina, método de preparação e uso do mesmo e composição farmacêutica contendo o mesmo
BRPI1011851A2 (pt) Composto, composição farmacêutica, e, métodos para induzir apoptose em uma célula, epara tratar uma doença
CR20150327A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
BR112015006243A2 (pt) agentes antibacterianos de fenicol
BR112013031759A2 (pt) forma cristalina de derivados de indazolil amida para o tratamento de distúrbios mediados pelo receptor de glicocorticoides
ECSP099328A (es) Análogos de pirazol
BR112014011262A8 (pt) compostos substituídos de carboxamida à base de pirazolila substituída e derivados de ureia, seus usos, e composição farmacêutica
AR077958A1 (es) Quinoxalinonas antagonistas de la hepcidina
GT201400044A (es) 2-(croman-6-iloxi)-tiazoles sustituidos y su uso como productos farmacéuticos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL